{"id":3212,"date":"2026-06-10T06:00:52","date_gmt":"2026-06-10T11:00:52","guid":{"rendered":"https:\/\/www.worldcare.com\/?p=3212"},"modified":"2026-08-22T21:01:00","modified_gmt":"2026-08-23T02:01:00","slug":"ce-le-spune-asiguratorilor-o-descoperire-recenta-in-cancerul-pancreatic-despre-opiniile-medicale-ale-expertilor","status":"publish","type":"post","link":"https:\/\/www.worldcare.com\/ro\/what-a-pancreatic-cancer-breakthrough-tells-insurers-about-expert-medical-opinions\/","title":{"rendered":"Ce le spune asigur\u0103torilor o descoperire avansat\u0103 \u00een cancerul pancreatic despre opiniile medicale ale exper\u021bilor"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"3212\" class=\"elementor elementor-3212\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b2feeaa e-flex e-con-boxed e-con e-parent\" data-id=\"5b2feeaa\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-baac94d elementor-widget elementor-widget-text-editor\" data-id=\"baac94d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Un medicament pe care oamenii de \u0219tiin\u021b\u0103 \u00eel numesc \u201cechivalentul cancerului al parcurgerii unei mile \u00een patru minute\u201d se apropie de aprobarea de c\u0103tre autorit\u0103\u021bile de reglementare. Daraxonrasib vizeaz\u0103 o protein\u0103 care declan\u0219eaz\u0103 aproape toate tumorile pancreatice - precum \u0219i multe tipuri de cancer pulmonar \u0219i de colon - \u0219i \u00eentr-un... <a href=\"https:\/\/ir.revmed.com\/news-releases\/news-release-details\/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit\/\" target=\"_blank\" rel=\"noreferrer noopener\">studiu pivot \u00een stadiu avansat,<\/a> aproape a dublat supravie\u021buirea median\u0103 la pacien\u021bii cu cancer pancreatic metastatic, de la 6,7 luni la 13,2 luni.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>Inova\u021bia este remarcabil\u0103 prin poten\u021bialul s\u0103u de a reinventa abord\u0103rile terapeutice \u0219i este comparat\u0103 cu impactul revolu\u021bionar al imunoterapiei de acum 15 ani.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>Este, de asemenea, remarcabil pentru locul \u00een care se \u00eencadreaz\u0103 \u00eentr-un model mai larg: \u00een timp ce descoperiri precum Daraxonrasib apar sporadic, cuno\u0219tin\u021bele medicale \u00een general avanseaz\u0103 \u00eentr-un ritm pe care niciun clinician individual, sistem de s\u0103n\u0103tate sau \u021bar\u0103 nu \u00eel poate absorbi pe deplin de unul singur - \u0219i, av\u00e2nd \u00een vedere c\u0103 opiniile medicale globale \u0219i multidisciplinare sunt mai accesibile ca niciodat\u0103 prin intermediul planurilor de s\u0103n\u0103tate, al asigur\u0103rilor de boli grave \u0219i chiar al serviciilor precum cardurile de credit sau avantajele de afinitate hotelier\u0103, acestea nu trebuie s\u0103 fac\u0103 acest lucru. \u00a0<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\"><strong>Ritmul inova\u021biei \u00een oncologie este un semnal de alarm\u0103 pentru planurile de s\u0103n\u0103tate<\/strong><\/h2>\n<p><!-- \/wp:heading --><!-- wp:paragraph --><\/p>\n<p>Progresele \u00een domeniul medicamentelor \u0219i al tehnologiei medicale ofer\u0103 indicatori tangibili pentru ritmul uimitor al inova\u021biei medicale. Lua\u021bi \u00een considerare ce s-a \u00eent\u00e2mplat doar \u00een ultimele luni:<\/p>\n<p><!-- \/wp:paragraph --><\/p>\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>\u00cencep\u00e2nd cu mai 2026, <a href=\"https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2026\" target=\"_blank\" rel=\"noopener\">Agen\u021bia European\u0103 pentru Medicamente<\/a>\u00a0emisese 36 de avize pozitive privind medicamente noi \u0219i 59 de avize suplimentare care prelungiser\u0103 utiliz\u0103rile aprobate ale tratamentelor existente.<\/li>\n<li><a href=\"https:\/\/www.canada.ca\/en\/health-canada\/news\/2026\/03\/new-task-force-to-enhance-canadas-competitiveness-and-improve-access-to-innovative-medicines.html\" target=\"_blank\" rel=\"noreferrer noopener\">Health Canada <\/a>a autorizat 56 de medicamente farmaceutice noi, 23 de medicamente biologice noi, 134 de medicamente farmaceutice generice \u0219i 12 biosimilare \u00eentre aprilie 2025 \u0219i februarie 2026. Dintre acestea, 43 con\u021bin ingrediente medicinale care nu au fost niciodat\u0103 aprobate pentru v\u00e2nzare \u00een Canada.<\/li>\n<li>\u00cencep\u00e2nd cu 1 iunie 2026, <a href=\"https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2026\" target=\"_blank\" rel=\"noreferrer noopener\">Administra\u021bia pentru Alimente \u0219i Medicamente din SUA<\/a> a aprobat 20 de medicamente noi, f\u0103r\u0103 a lua \u00een considerare noile indica\u021bii.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n<p><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>Ritmul inova\u021biei \u00een oncologie, \u00een special, continu\u0103 s\u0103 se accelereze. \u00cen ultimul deceniu, au fost aprobate 115 tratamente \u00eempotriva cancerului pentru primele 10 tipuri de cancer cele mai prevalente - fa\u021b\u0103 de 28 de aprob\u0103ri \u00een deceniul precedent, potrivit unui raport. <a href=\"https:\/\/www.airfinity.com\/articles\/300-rise-in-approved-new-cancer-treatments-in-the-last-two-decades-with-us\" target=\"_blank\" rel=\"noreferrer noopener\">Analiza Airfinity<\/a> care men\u021bioneaz\u0103, de asemenea, c\u0103 o parte semnificativ\u0103 sunt tratamente combinate utilizate \u00een terapii \u021bintite.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:heading --><\/p>\n<h2 class=\"wp-block-heading\"><strong>Opiniile medicale secundare multidisciplinare ajut\u0103 asigur\u0103torii s\u0103 elimine decalajul de cuno\u0219tin\u021be<\/strong><\/h2>\n<p><!-- \/wp:heading --><!-- wp:paragraph --><\/p>\n<p>Cuno\u0219tin\u021bele medicale sunt acum estimate la <a href=\"https:\/\/connection.asco.org\/do\/staying-current-todays-era-rapidly-evolving-medical-advances#:~:text=1,decade%20from%202010%20to%202020.%E2%80%9D\" target=\"_blank\" rel=\"noreferrer noopener\">dublu la fiecare 73 de zile<\/a>, potrivit Societ\u0103\u021bii Americane de Oncologie Clinic\u0103. Niciun medic nu poate \u021bine pasul cu asta. Dup\u0103 cum a spus chirurgul \u0219i autorul Atul Gawande <a href=\"https:\/\/www.newyorker.com\/news\/news-desk\/cowboys-and-pit-crews\" target=\"_blank\" rel=\"noreferrer noopener\">a sus\u021binut<\/a>, medicina a devenit prea complex\u0103 pentru modelul expertului individual. Standardul modern necesit\u0103 \u00eengrijire specializat\u0103 multidisciplinar\u0103, bazat\u0103 pe echip\u0103.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>Aici este locul <a href=\"http:\/\/worldcarestage.wpengine.com\" target=\"_blank\" rel=\"noreferrer noopener\" data-type=\"link\" data-id=\"worldcarestage.wpengine.com\">opinii medicale secundare la nivel global <\/a>devin critice. C\u00e2nd un pacient din Polonia, Canada sau Arabia Saudit\u0103 prime\u0219te un diagnostic grav, rezultatul s\u0103u depinde de accesul echipei sale de \u00eengrijire la speciali\u0219tii care cunosc cele mai recente dovezi \u0219i le pot aplica cazului s\u0103u specific.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>O descoperire avansat\u0103 care se apropie de aprobarea FDA sau EMA ast\u0103zi ar putea deveni standardul de \u00eengrijire \u00een decurs de un an. Pentru planurile de s\u0103n\u0103tate de grup, poli\u021bele pentru boli grave \u0219i TPA-urile care deservesc membri din America de Nord, Europa, Africa \u0219i Golful, un serviciu interna\u021bional de opinie medical\u0103 expert\u0103 nu mai este o ofert\u0103 suplimentar\u0103 - este o \u00eembun\u0103t\u0103\u021bire a beneficiilor care afecteaz\u0103 direct calitatea \u00eengrijirii primite de membri \u0219i acurate\u021bea afirma\u021biilor care urmeaz\u0103.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p>Oferirea accesului la opinii secundare din partea echipelor multidisciplinare pentru diagnostice grave \u0219i complexe este una dintre cele mai clare forme de inovare \u00een domeniul beneficiilor de grup disponibile asigur\u0103torilor \u00een prezent. \u00centr-o pia\u021b\u0103 \u00een care cuno\u0219tin\u021bele medicale se acumuleaz\u0103 mai repede dec\u00e2t poate urm\u0103ri orice medic, aceasta este, de asemenea, una dintre cele mai justificabile.<\/p>\n<p><!-- \/wp:paragraph --><!-- wp:paragraph --><\/p>\n<p><!-- \/wp:paragraph --><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>A drug that scientists are calling \u201ccancer&#8217;s equivalent of breaking the four-minute mile\u201d is nearing regulatory approval. Daraxonrasib targets a protein that drives nearly all pancreatic tumors \u2014 as well as many lung and colon cancers \u2014 and in a late-stage pivotal trial, it nearly doubled median survival in patients with metastatic pancreatic cancer from [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":3256,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[158,35,16],"tags":[],"class_list":["post-3212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-innovation","category-cancer","category-medical-second-opinion"],"_links":{"self":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts\/3212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/comments?post=3212"}],"version-history":[{"count":0,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/posts\/3212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/media\/3256"}],"wp:attachment":[{"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/media?parent=3212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/categories?post=3212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.worldcare.com\/ro\/wp-json\/wp\/v2\/tags?post=3212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}